CGTG-102 (Ad5/3-D24-GMCSF), a novel oncolytic adenovirus, in patients with refractory solid tumors: Experience from an advanced therapy access program.

@article{Euler2012CGTG102A,
  title={CGTG-102 (Ad5/3-D24-GMCSF), a novel oncolytic adenovirus, in patients with refractory solid tumors: Experience from an advanced therapy access program.},
  author={M. V. Euler and A. Kanerva and P. Nokisalmi and A. Koski and Iulia Diaconu and V. Cerullo and T. Joensuu and M. Oksanen and S. Pesonen and L. Kangasniemi and T. Ranki and Raita Heiskanen and Akseli Hemminki},
  journal={Journal of Clinical Oncology},
  year={2012},
  volume={30}
}
  • M. V. Euler, A. Kanerva, +10 authors Akseli Hemminki
  • Published 2012
  • Medicine
  • Journal of Clinical Oncology
  • e13035 Background: Following preclinical testing CGTG-102, a 5/3 chimeric oncolytic adenovirus armed with human GMCSF, has been used to treat 115 refractory cancer patients. Methods: Eligibility criteria included refractory advanced solid tumors, no major organ deficiencies and written informed consent. Patients were treated with either a single treatment or serial treatments with one or more viruses. Intra tumoral administration was performed under ultrasound guidance. The initial dose, 8 x… CONTINUE READING

    Topics from this paper